Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,087 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate-severe Pain Clear all
Withdrawn Phase 1 Interventional

Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02767349
View directory record Official record
Conditions
Acute Pain
Interventions
MNK-155
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

NCT04203797
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

NCT03421197
View directory record Official record
Conditions
Psoriasis
Interventions
PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
74
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caregiver Wellness After Traumatic Brain Injury (CG-WELL): An Intervention Designed to Promote Well-being in Caregivers of Acute Moderate to Severe Traumatic Brain Injuries

NCT05307640
View directory record Official record
Conditions
Trauma, Brain
Interventions
CG-Well, Information Support & Referral (ISR)
Behavioral
Lead sponsor
Natalie Kreitzer
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Shreveport, Louisiana • Wyoming, Michigan • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 4 Interventional

Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib

NCT00348491
View directory record Official record
Conditions
Pain
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
17 Years and older
Enrollment
364 participants
Timeline
Started 2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
29
States / cities
Scottsdale, Arizona • Bradenton, Florida • Brandon, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Compare Genetic Variations of IGF-I and IGF-II

NCT01329523
View directory record Official record
Conditions
Dementia
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
50 Years to 81 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

NCT07231991
View directory record Official record
Conditions
Healthy Participants
Interventions
vepdegestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

NCT01295710
View directory record Official record
Conditions
GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions
US-ATG-F, Placebo
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

NCT06613360
View directory record Official record
Conditions
SLE, SLE (Systemic Lupus)
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Avondale, Arizona • Tucson, Arizona • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 3, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

NCT04946318
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Results available

ED Initiated Oral Naltrexone for AUD

NCT04817410
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Emergency Department Initiated Oral Naltrexone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

NCT06020014
View directory record Official record
Conditions
Asthma
Interventions
AZD4604, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

NCT03052751
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
UCB7665, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

NCT00126763
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Phoenix, Arizona • Loma Linda, California • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 3, 2026, 5:13 AM EDT